2026 December Quarter Financial Results Briefing

Performance Overview

In the first quarter of the 2026 December term, net sales reached 6,128 million yen (up 38.5% YoY), and operating profit was 2,079 million yen (up 90.2% YoY). Pharmaceutical sales increased to 5,997 million yen (up 41.5% YoY), and shipment volume rose to 12,978 tons (up 26.7% YoY). Sales of major products also increased YoY, with CZ series up 41.4%, SF up 37.1%, EXE up 26.8%, and V-Bond up 18.4%. FX effects contributed a positive impact of 286 million yen on net sales and 166 million yen on operating profit.

Outlook for the Future

Full-year earnings guidance projects net sales of 24,500 million yen (up 17.0% YoY), operating profit of 7,600 million yen (up 32.2% YoY), and net income of 5,550 million yen (up 10.4% YoY). Mid- to long-term growth is expected driven by technological innovations related to IoT, AI, 5G/6G, electric and autonomous vehicles, DX and GX advancements, and expansion of related markets. Particularly, increased demand for semiconductor package substrates and ultra-high-density products is expected to boost demand for 'CZ series' and 'Chemical Adhesion Enhancers.' While short-term fluctuations in the semiconductor market may affect key products, long-term demand growth is anticipated.